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Abstract
Retroperitoneal fibrosis (RPF), is a rare fibroinflammatory disease. The pathogenesis of RPF is still unclear and numerous theories have 
been reported such as environmental factors, immunologic process, genetic component, local inflammation and advanced atherosclerosis.
RPF is characterized by the presence of a particular retroperitoneal fibrotic tissue which is white, woody and involving retroperitoneal 
structures such as the great vessels, ureters and psoas muscle. The main complication of RPF is the obstruction of local structures such as 
the ureters due to the fibrosis and the treatment of this aspect represents the main challenge for this pathology.
RPF medical treatment consists of corticosteroids or/and immunosuppressive therapy. We report a case of a patient (63y/o) affected by 
idiopathic RPF treated with low-dose methotrexate (MTX) and 6-methylprednisolone (6-MP) for two years, describing and confirming the 
effectiveness and safety of a long-term low-dose MTX and 6-MP treatment.
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Introduction
Retroperitoneal fibrosis (RPF), also known as Ormond’s disease, is a 
rare fibroinflammatory disease with uncertain etiology and its clinical 
features and diagnostic appearance are very different.
It was first described in 1905 by the French urologist Albarran, but it 
became fully recognized and established as a clinical entity only in 
1948 by Ormond 1,2. The true incidence of RPF is uncertain, anyway the 
literature reports a range from one case per 200,000 to 500,000 peo-
ple per year and a male predisposition (3:1 male/female ratio) in the 
fifth and sixth decade of life 3.
RPF is characterized by the presence of a particular retroperitoneal 
fibrotic tissue which is white, woody and involving retroperitoneal 
structures such as the great vessels, ureters and psoas muscle. Usually 
it develops around the infrarenal part of the aorta and the iliac arter-
ies, sometimes spread down to the pelvis and rarely it extends to the 
scrotum or up to the diaphragm 3. Retroperitoneal fibrosis is generally 
idiopathic (about 66% of cases), but can also be secondary to surgery, 
particular drugs, malignant neoplasms, radiation and infections 4. We 
can define a true idiopathic RPF when a potential specific cause or a 
multi-organ disease are not identified 5-8. The pathogenesis of RPF is 
still unclear and numerous theories have been reported such as en-
vironmental factors, immunologic process, genetic component, local 
inflammation and advanced atherosclerosis 9. Recent studies support 
the hypothesis that the disease may be caused by a chronic inflam-
matory state triggered and maintained by autoimmune responses 
10. The surgical treatment of idiopathic RPF acts only on the ureteral 
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artery, the distal segment of right ureter with hydroureteronephro-
sis upstream (Fig. C-D, arrows) and infiltrates the right postero-lateral 
corner of the bladder (Fig. 1A, arrowhead), the right ureteral opening 
and the body of uterus.
This inhomogeneous solid tissue (cross diameter of 5.7 cm, anteropos-
terior diameter of 3.4 cm) showed a slight enhancement after contrast 
agent injection in late phase and was compatible with the diagnosis of 
retroperitoneal fibrosis (Figure 1A-D).
Our team confirmed the clinical diagnosis of idiopathic RPF and re-
quired further blood tests before starting drug treatment. The pa-
tient had positive antinuclear antibodies (ANA). Then she started the 
therapy with low-dose MTX at a weekly dose of 10 mg and low-dose 
6-methyl- prednisolone (6-MP) therapy (4 mg/daily). After ten days of 
treatment the patient was completely asymptomatic, all blood tests 
were normal and then she was discharged.
CT scan performed in march of 2015 after one year of treatment 
showed “subtotal resolution”) of the fibrotic mass (Fig. 1 E-F) At two-
years follow-up after the diagnosis of idiopathic RPF, the patient was 
completely asymptomatic and the abdominal CT scan has showed a 
complete regression of the retroperitoneal fibrotic mass without any 
sign of relapse.
Actually the patient is completely asymptomatic.
Discussion
PF is a rare fibroinflammatory disease with uncertain etiology, charac-
terized by the presence of a particular retroperitoneal fibrotic tissue 
which is white, woody and involving retroperitoneal structures such 
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obstruction without preventing disease progression and relapses and 
the treatment of this aspect represents the main challenge for this pa-
thology. The ureteral entrapment is often silent and progressive and 
the early patients’ clinical manifestations are fever, abdominal or back 
pain, weight loss, asthenia, dysuria and oliguria 11. Since the Sixties of 
the last century, many medical therapies have been proposed such 
as corticosteroids and immunosuppressants  . From the beginning of 
the Nineties, was introduced the tamoxifen, alone or as a second- line 
treatment because of its interference with the fibrogenic process 17. 
We report one case of a patients affected by idiopathic RPF treated 
with low-dose methotrexate (MTX) and 6-methylprednisolone (6-MP) 
for two years, describing and confirming the effectiveness and safety 
of a long-term low-dose MTX and 6-MP treatment.
Case Series
In a 63 year old caucasian female was hospitalized in our Department 
due to persisting bilateral low back pain. The patient reported arterial 
hypertension in good control. She denied, autoimmune diseases, pre-
vious important infections or radiotherapy. Just recovered she was in 
good haemodinamic status, no fever but showing pain in both renal 
fossae and mild arterial hypertension (150/95 mmHg). The following 
blood abnormalities were present: erytrocite sedimentation rate (ESR) 
90 mm/hr; C-reactive protein (CRP) 50 mg/dl; serum urea nitrogen 72 
mg/dl; serum creatinine 1.5 mg/dl; serum potassium 5.1 mEq/L; red 
blood cells 3,200,000/mm3; Hb 11.9 g/dl; albumin 50.2%; alfa-1 globulins 
5.2%; fibrinogen 645 mg/dL. The abdominal ultrasound study showed 
severe right hydroureteronephrosis with periaortic inhomogeneous 
hypoechoic tissue. Abdominal contrast-enhanced computed tomog-
raphy (CT) scan revealed the presence of a gross, poorly-bordered, 
infiltrating tissue occupying pre-sacral and right obturator spaces, and 
extending along the mesorectal fascia (Fig. 1A-B, arrows). This tissue 
encased the right sciatic nerve, branches of the right internal iliac
as the great vessels, ureters and psoas muscle. When the fibrotic mass 
has a large extension, it can obstruct the ureters. Specimens collected 
early in the course of the disease are constituted by collagen bundles, 
fibroblasts, plasma cells and lymphocytes, confirming that the basis 
of the disease is an exuberant immunologic processes 18. In the early 
phases, there is an inflammatory infiltrate of both B (CD 20+) and T 
(CD 4+) lymphocytes, plasma cells, macrophages (CD68+) and histio-
cytes and sometimes fibrinoid necrosis of medium-sized and capillary 
retroperitoneal vessels is also detected 19,20. As a possible genetic pre-
disposition of idiopathic RPF, besides the old association with HLA-B27 
antigen, a further clue has been studied because of its significant as-
sociation with HLA-DRB1*03, an allele linked to other autoimmune 
diseases 21. The most common symptoms are low back or abdominal 
pain and sometimes fever. Blood tests may often show raised acute 
phase reactants as ESR (erytrocite sedimentation rate), CRP (C-reac-
tive protein), 2-globulins which reflect the disease activity, its natural 
course and the eventual relapses 22. The laboratory tests include the 
complete blood count, renal function profile (creatinine levels, serum 
electrolyte concentration), the assay of antineutrophil cytoplasmatic 
antibodies (ANCA), antinuclear antibodies (ANA), anti-thyroglobu-
lin antibodies, anti-smooth muscle antibodies (ASMA), rheumatoid 
factor, and furthermore IgG and IgG4 serum levels 23,24. To reach the 
correct diagnosis CT and MRI are very useful 25 and in doubtful cases 
a biopsy is performed11. More recently FDG-PET and PET/CT are feasi-
ble and suitable imaging methods useful to reach a correct diagnosis 
and to monitor the response to therapy 26. In complicated cases or 
unresponsive to therapy, the ureteral stenting may not be sufficient 
and then a surgical treatment is necessary. The surgical treatment of 
choice is laparoscopic or open ureterolysis; the ureter is dissected free 
from the fibrotic mass laterally or intraperitoneally. There is also an 
alternative thecnique through which the ureter is wrapped with omen-
tum to avoid the entrapment by the fibrosis 25. Currently with the in-
troduction of robotic surgery, some surgeons have begun to use it for 
the ureterolysis 27. The surgical or endoscopic (ureteral stenting) treat-
ment must be combined with drug therapy in or- der to avoid relapses 
of disease 33. Some Authors combine corticosteroid and immunosup-
pressive therapy. Others give only
corticosteroid or immunosuppressive agents 25. Kisiel B et al 28 showed 
azathioprine to be particularly effective in the treatment of RPF. 
Multi-targeted bio-therapy as TNF-blocking antibodies, JaKs-STATS 
complex inhibitors and anti-human CD2O anti- bodies, either alone or 
combined with steroids/immunosuppressants, could represent an in-
teresting and challenging approach for the management of idiopathic 
RPF 29. Actually, there are many studies about the therapeutic poten-
tial of F8-IL10 (antibody F8 fused to anti-inflammatory IL10) and the 
use of phosphodiesterase-4 (PDE4) inhibitors 30,31. As reported from 
Alberti, in the last two decades we did not have any interesting inno-
vation about diagnosis and therapy of RPF but only many pathogenet-
ic news 32. The prognosis of RPF is surprisingly good with treatment. 
However, the disease may be very insidious with unpredictable pro-
gression. All the authors agree that RPF may persist or recur also some 
years later and a strict follow-up is necessary all life long. The rapid clin-
ical and laboratory improvement and the progressive reduction of the 
fibrotic tissue, shown by CT scan, in this case report, lead us to affirm 
and confirm (as in our first experience of 1995)12 that long-term low-
dose MTX and 6 MP therapy is a particularly safe and effective therapy 
on idiopathic RPF which avoids more invasive surgical treatments.
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